Notable 52-Week Highs and Lows of the Day 09/24: (FB) (FU) (YHOO) High; (BIOS) (JCP) (SQNM) Low

September 24, 2013 2:18 PM EDT
52-Week High:
  • Facebook, Inc. (Nasdaq: FB) $49.66. Facebook popping today as another firm felt a shift in sentiment toward the social network giant. Citi upgraded the stock to Buy today while boosting its price target from $32 up to $55. Analyst Mark May thinks recent factors driving the sudden inflection in ad growth are sustainable. For more color on the move, click here.

  • FAB Universal Corp. (AMEX: FU) $9.74. FAB up after announcing that it entered an agreement with Future TV Co. Ltd. to distribute its copyright-protected media content through pay-TV terminals used in the home by Future TV’s subscribers.

  • Yahoo! (Nasdaq: YHOO) $31.54. Yahoo! moving to new highs as momentum is continuing in the name. Earlier Tuesday, AOL Inc. (NYSE: AOL), Microsoft Corp. (Nasdaq: MSFT), and Yahoo! announced that they have each committed to converge around a common set of API specifications for the premium programmatic digital advertising sales channel. For more on the collaboration, click here.

  • Catalyst Pharmaceutical Partners (Nasdaq: CPRX) $3.24. Maxim Group started Catalyst at Buy with a generous $4 price target, a suggested premium of 39 percent from Monday's close at $2.87.
52-Week Low:
  • BioScrip Inc. (Nasdaq: BIOS) $8.52. BioScript seeing some massive selling at the $10 to $10.20 level. There was a press release issued Monday night from a law firm looking to scrounge up investors for a class action. Short interest on the name is at 3.26 million shares, or 7.5 percent of float.

  • J. C. Penney Company, Inc. (NYSE: JCP) $11.90. JCPenney lower today amid market chatter that the retailer might be planning a fresh round of capital raising. Nothing has been confirmed by the company yet. Looks like Vornado might have gotten out while the getting was good.

  • Sequenom, Inc. (Nasdaq: SQNM) $2.58. Sequenom announced that its Board of Directors has authorized a review of potential strategic alternatives for its Genetic Analysis business segment. The review will include evaluation of a full range of potential strategic alternatives for the Genetic Analysis business segment. Shares fell 6.5 percent to the new, 52-week low today.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Citi, Maxim Group

Add Your Comment